The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or reversible obstructive airway disease. “Metered dose inhalers like these are known as complex generics, which are traditionally harder to copy because of their complex formulation or mode of delivery,” said FDA Commissioner Stephen Hahn, M.D. “As a result, too many complex drugs lack generic competition even after patents and exclusivities no longer block generic approval. Supporting development and approval of generic copies of these complex medicines so that these products can get to patients has been a major focus of our efforts to improve competition and access and to lower drug prices.”

Related News Articles

Headline
Leaders of the House Energy and Commerce and Senate Finance committees today asked Health and Human Services Secretary Alex Azar to clarify by June 10 the…
Headline
The Campaign for Sustainable Rx Pricing, for which AHA is a founding member, today launched a petition and digital ad urging drug companies to suspend their “…
Headline
An estimated 9.5% of U.S. residents, or 30.7 million people, lacked health insurance when surveyed in the first six months of 2019, according to preliminary…
Perspective
On Tuesday, the Census Bureau reported that “a third of Americans now show signs of clinical anxiety or depression” due to the COVID-19 pandemic. It’s also…
Headline
The Centers for Medicare & Medicaid Services yesterday released a fact sheet for state and local governments seeking Medicare, Medicaid or Children’s…
Headline
An annual report into death by several factors tied to mental health and wellbeing — otherwise referred to as “deaths of despair” — topped 150,000 in 2018. The…